New trial tests shorter treatment for rare blood cancer
NCT ID NCT07169565
Summary
This early-stage study is testing whether a three-drug combination can effectively control Waldenström Macroglobulinemia when given for a fixed period instead of indefinitely. Researchers will first find the safest dose of one drug, then test that dose in more patients to see how well the treatment works and how long benefits last. The goal is to help patients achieve good disease control without needing lifelong medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA (WM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.